Emerging biologics in inflammatory bowel disease

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Biologic therapy, particularly anti-tumor necrosis factor (anti-TNF) agents, is recommended for inflammatory bowel disease (IBD) patients with poor prognostic factors or refractory disease.
• However, primary non-response and secondary loss of response to anti-TNF agents occur in a significant proportion of patients, alongside potential side effects and high costs.

Purpose of the Study:

• To review the mechanisms of action, efficacy, and safety of novel therapeutic agents for IBD.
• To discuss the role and efficacy of biosimilars in IBD treatment.

Main Methods:

• Review of existing literature on novel small molecules, cellular therapies, and biosimilars for IBD.
• Analysis of efficacy and safety data for agents including JAK inhibitors, interleukin inhibitors, SMAD7 antisense oligonucleotides, and anti-integrin inhibitors.

Main Results:

• Novel agents like tofacitinib (JAK inhibitor), ustekinumab (interleukin inhibitor), mongersen (SMAD7 antisense oligonucleotide), and vedolizumab (anti-integrin inhibitor) offer new treatment avenues.
• Biosimilars provide a lower-cost alternative with comparable efficacy to reference biologics for IBD.

Conclusions:

• A range of novel biologic and small molecule therapies are emerging for IBD, addressing limitations of current treatments.
• Biosimilars are a cost-effective option that expands treatment accessibility for IBD patients.